LGVN
Longeveron Inc.
-3.70 (-55.46%)2.98USD1.1M成交股數93.3M市值–本益比(近四季)78.6股價營收比-9.2%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 287K-25% | 398K-34% | 137K-82% | 316K-32% | 381K-30% | 603K+302% | 773K+256% | 468K+68% | 548K | 150K | 217K | 279K |
| 營業成本 | 105K | 134K | 12K | 170K | 106K | 74K | 91K | 124K | 219K | 96K | 124K | 203K |
| 毛利 | 182K-34% | 264K-50% | 125K-82% | 146K-58% | 275K-16% | 529K+880% | 682K+633% | 344K+353% | 329K | 54K | 93K | 76K |
| 毛利率 | 63.4% | 66.3% | 91.2% | 46.2% | 72.2% | 87.7% | 88.2% | 73.5% | 60.0% | 36.0% | 42.9% | 27.2% |
| 研發費用 | 3.2M | 2.3M | 3.9M | 3.0M | 2.5M | 2.0M | 2.2M | 1.7M | 2.2M | 1.8M | 2.3M | 2.8M |
| 銷售管理費用 | 3.2M | 2.7M | 3.6M | 2.6M | 2.9M | 2.8M | 3.1M | 2.1M | 2.2M | 3.4M | 3.5M | 2.0M |
| 營業利益 | −6.2M+19% | −4.8M+11% | −7.3M+57% | −5.4M+54% | −5.2M+27% | −4.3M-17% | −4.6M-19% | −3.5M-26% | −4.1M | −5.2M | −5.7M | −4.7M |
| 營業利益率 | -2,150.2% | -1,199.7% | -5,335.8% | -1,707.9% | -1,359.8% | -710.3% | -601.4% | -747.9% | -746.4% | -3,440.7% | -2,632.3% | -1,690.3% |
| 稅後淨利 | −6.1M+21% | −4.7M+16% | −7.2M+63% | −5.0M+47% | −5.0M+23% | −4.1M-20% | −4.4M-22% | −3.4M-27% | −4.1M | −5.1M | −5.6M | −4.6M |
| 淨利率 | -2,116.0% | -1,189.9% | -5,270.8% | -1,591.1% | -1,315.2% | -677.1% | -571.7% | -729.3% | -740.5% | -3,404.0% | -2,595.4% | -1,665.6% |
| 稀釋 EPS | -0.19-44% | -0.19-116% | -0.39+15% | -0.33-82% | -0.34-79% | 1.16-142% | -0.34-87% | -1.83-17% | -1.61 | -2.79 | -2.67 | -2.21 |
| 稀釋股數 | 31.4M | 24.79B | 18.37B | 15.0M | 14.95B | 9.41B | 13.63B | 6.51B | 2.51B | 2.12B | 2.1M | 2.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 10.1M | 15.8M | 9.2M | 10.3M | 14.3M | 19.2M | 22.8M | 12.4M | 1.9M | 2.0M | 2.7M | 1.9M |
| 應收帳款 | 65K | 68K | 52K | 31K | 29K | 84K | 380K | 218K | 178K | 96K | 96K | 96K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 15.5M | 21.2M | 15.6M | 16.7M | 20.8M | 25.6M | 29.9M | 19.4M | 9.7M | 11.6M | 17.1M | 21.8M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 5.1M | 5.2M | 5.6M | 4.1M | 3.7M | 3.7M | 4.3M | 4.5M | 6.7M | 5.0M | 5.8M | 5.5M |
| 股東權益 | 10.4M | 16.0M | 10.0M | 12.7M | 17.2M | 21.9M | 25.6M | 14.9M | 3.0M | 6.6M | 11.3M | 16.3M |
| 負債比 | 32.8% | 24.4% | 35.9% | 24.4% | 17.7% | 14.4% | 14.3% | 23.1% | 68.6% | 43.0% | 34.1% | 25.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −4.4M | – | – | −4.7M+52% | – | – | – | −3.1M | – | – | −5.8M |
| 資本支出 | – | 0.00 | – | – | 27K | – | – | – | 16K | – | – | 42K |
| 自由現金流 | – | −4.4M | – | – | −4.7M+52% | – | – | – | −3.1M | – | – | −5.9M |
| 折舊攤銷 | 200K | 200K | 200K | 200K | 200K | 100K | 200K | 200K | 200K | 200K | 200K | 200K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -1,098.0% | – | – | -1,239.9% | – | – | – | -566.1% | – | – | -2,111.1% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 1.2M
| Reportable Segment Aggregation Before Other Operating | 1.2M | 100.0% | -49.9% |
|---|
產品／服務2025 年度 · 1.2M
| Clinical Trial Revenue | 954K | 79.6% | -32.0% |
|---|---|---|---|
| Contract Manufacturing Revenue | 222K | 18.5% | -54.4% |
| Contract Manufacturing Lease Revenue | 23K | 1.9% | -95.4% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.2M | -49.9% | −22.7M | -1,893.6% | -1.29 | −18.9M |
| FY2024 | 2.4M | +237.4% | −16.0M | -667.8% | -2.62 | −14.5M |
| FY2023 | 709K | -42.0% | −21.4M | -3,020.2% | -10.22 | −19.3M |
| FY2022 | 1.2M | -6.4% | −18.8M | -1,541.3% | -0.90 | −14.5M |
| FY2021 | 1.3M | -76.8% | −17.0M | -1,305.1% | -0.90 | −10.0M |
| FY2020 | 5.6M | – | −3.7M | -66.1% | -0.23 | −2.5M |